There are 2789 resources available
571P - Real-life monocentric, retrospective study on efficacy and tolerability of lenvatinib (Len) in patients (pts) with advanced radioactive iodine–refractory differentiated thyroid cancer (rDTC)
Presenter: Stefania Zovato
Session: ePoster Display
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Presenter: Javier Pozas
Session: ePoster Display
573P - Panorama of genomic RET alterations (GA) in the major subtypes of thyroid carcinomas (TC)
Presenter: Daniel Bowles
Session: ePoster Display
574P - Clinical impact of the GAPP score and SDHB negativity in patients with pheochromocytoma/paraganglioma
Presenter: Akihiro Ohmoto
Session: ePoster Display
583P - Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Presenter: Vincenza Conteduca
Session: ePoster Display
584P - Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Stephane Oudard
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display
586P - Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: ePoster Display
587P - Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
Presenter: Alicia Morgans
Session: ePoster Display
588P - Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial
Presenter: Klara Kvorning Ternov
Session: ePoster Display